• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 711-716.DOI: 10.3969/j.issn.1671-2587.2026.05.007

Previous Articles     Next Articles

Analysis on the Safety and Efficacy of Perioperative Transfusion of Frozen-Thawed Deglycerolized Red Blood Cells in Patients with Solid Tumors

LI Jinqi, XIA Lili, LIU Jiayi, ZHOU Mei, WANG Xingyi, GU Haihui   

  1. Blood Transfusion Department, First Affiliated Hospital of Naval Military Medical University, Shanghai 200433
  • Received:2026-09-02 Revised:2026-09-22 Online:2026-10-20 Published:2026-11-11

Abstract: Objective To evaluate the safety profile of transfusing frozen-thawed deglycerolized red blood cells (FTDRBCs) in patients with solid tumors, and to explore its application value in different clinical scenarios and significance for perioperative blood support. Methods A retrospective analysis was conducted on transfusion data from 100 patients with solid tumors treated between June 2025 and June 2026. Patients were divided into the intraoperative bleeding group (n=75) and the anemia correction group (n=25) based on the timing of the first FTDRBC transfusion.Using the transfusion episode as the analytical unit, we collected data on Hb before and after transfusion, unit transfusion efficiency (ΔHb/U), 72-hour subsequent red blood cell requirement rate, and total red blood cell exposure. Safety evaluation included dynamic changes in liver and renal function, coagulation parameters, and transfusion-related adverse reactions. The paired Wilcoxon test was used to analyze Hb changes before and after transfusion, the Mann-Whitney U test for between-group comparisons, and the chi-square test for comparing subsequent requirement rates between groups. Results In the intraoperative bleeding group, the baseline Hb was 71 (61, 83) g/L, and the median ΔHb at 24 h post-transfusion was 7 (2, 14) g/L (Z=-5.29, P<0.001); in the anemia correction group, the baseline Hb was 68 (55, 80.3) g/L, and the 24 h ΔHb was 7 (3.5, 10) g/L (Z=-3.99, P<0.001). In the transfusion-free subgroup without additional red blood cell transfusions within 72 h, the 48 h ΔHb in the two groups were 8 (-0.75, 18.75) and 8 (0.5, 19.5) g/L, respectively (Z=-0.079, P=0.937), and the 72 h ΔHb were 8.5 (-5, 15.75) and 12 (3.5, 26.5) g/L, respectively (Z=-1.099, P=0.272). The 72-hour subsequent red blood cell requirement rates in the two groups were 47% (35/75) and 32% (8/25), respectively, with no statistically significant difference (χ2=1.646, P=0.200). Multivariate linear regression showed that there was no significant correlation between storage days and 24 h ΔHb/u (P=0.520). Regarding safety, no statistically significant differences were observed in TBil, Cr, AST, ALT, APTT, TT, FIB, PT or D-dimer before and after transfusion; no transfusion-related adverse reactions were observed among the 100 patients. Conclusion Patients with solid tumors demonstrated a distinct Hb increase following the transfusion of FTDRBC. No statistically significant difference in ΔHb was observed between the two scenarios, and the need for subsequent transfusions remained controllable within 72 hours post-transfusion. Prolonged storage (with a median duration of 928 days) did not compromise transfusion efficacy. No evidence of liver or kidney function impairment, nor coagulation dysfunction, was detected, and no transfusion-related adverse reactions were reported. In contexts of limited blood resources or scarce rare blood type reserves, FTDRBC exhibits favorable safety and efficacy profiles in perioperative transfusion management for patients with solid tumors.

Key words: Frozen-thawed deglycerolized red blood cells, Solid tumors, Patient blood management, Transfusion safety, Perioperative anemia

CLC Number: